[go: up one dir, main page]

FR3078781B1 - Methode d'isolement et de detection de cellules souches cancereuses - Google Patents

Methode d'isolement et de detection de cellules souches cancereuses Download PDF

Info

Publication number
FR3078781B1
FR3078781B1 FR1800202A FR1800202A FR3078781B1 FR 3078781 B1 FR3078781 B1 FR 3078781B1 FR 1800202 A FR1800202 A FR 1800202A FR 1800202 A FR1800202 A FR 1800202A FR 3078781 B1 FR3078781 B1 FR 3078781B1
Authority
FR
France
Prior art keywords
lectin
stem cells
eel
mah
lectins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1800202A
Other languages
English (en)
Other versions
FR3078781A1 (fr
Inventor
Vincent Carre
Aurelie Lacroix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Carcidiag Biotechnologies SAS
Original Assignee
Carcidiag Biotechnologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carcidiag Biotechnologies SAS filed Critical Carcidiag Biotechnologies SAS
Priority to FR1800202A priority Critical patent/FR3078781B1/fr
Priority to EP19715169.9A priority patent/EP3762727A1/fr
Priority to CA3093388A priority patent/CA3093388A1/fr
Priority to PCT/FR2019/050516 priority patent/WO2019171010A1/fr
Priority to US16/979,062 priority patent/US12109248B2/en
Priority to JP2020547131A priority patent/JP2021516342A/ja
Publication of FR3078781A1 publication Critical patent/FR3078781A1/fr
Application granted granted Critical
Publication of FR3078781B1 publication Critical patent/FR3078781B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • G01N33/57557—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C12N5/0695—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G01N33/57515—
    • G01N33/5756—
    • G01N33/5758—
    • G01N33/5759—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
    • G01N2333/42—Lectins, e.g. concanavalin, phytohaemagglutinin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

La présente invention concerne l'utilisation in vitro d'au moins une lectine pour le marquage de cellules souches cancéreuses d'organes cibles de cancers hormono-dépendants, choisie parmi les lectines Maackia amurensis lectin II (MAH-II), Euonymus europaeus lectin (EEL), Psophocarpus tetragonolobus lectin I (PTL-I) et Griffonia Simplicifolia lectin II (GSL-II), pour obtenir des cellules souches cancéreuses d'organes cibles de cancers hormonodépendants marquées, dans un échantillon biologique. notamment au moins deux lectines choisies parmi MAH-II, EEL, PTL-I et GSL-II, en particulier les deux lectines MAH-II et EEL.
FR1800202A 2018-03-08 2018-03-08 Methode d'isolement et de detection de cellules souches cancereuses Active FR3078781B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1800202A FR3078781B1 (fr) 2018-03-08 2018-03-08 Methode d'isolement et de detection de cellules souches cancereuses
EP19715169.9A EP3762727A1 (fr) 2018-03-08 2019-03-07 Methode d'isolement et de detection de cellules souches cancereuses
CA3093388A CA3093388A1 (fr) 2018-03-08 2019-03-07 Methode d'isolement et de detection de cellules souches cancereuses
PCT/FR2019/050516 WO2019171010A1 (fr) 2018-03-08 2019-03-07 Methode d'isolement et de detection de cellules souches cancereuses
US16/979,062 US12109248B2 (en) 2018-03-08 2019-03-07 Method for isolating and detecting cancer stem cells
JP2020547131A JP2021516342A (ja) 2018-03-08 2019-03-07 癌幹細胞の単離及び検出方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1800202 2018-03-08
FR1800202A FR3078781B1 (fr) 2018-03-08 2018-03-08 Methode d'isolement et de detection de cellules souches cancereuses

Publications (2)

Publication Number Publication Date
FR3078781A1 FR3078781A1 (fr) 2019-09-13
FR3078781B1 true FR3078781B1 (fr) 2021-01-08

Family

ID=62597575

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1800202A Active FR3078781B1 (fr) 2018-03-08 2018-03-08 Methode d'isolement et de detection de cellules souches cancereuses

Country Status (6)

Country Link
US (1) US12109248B2 (fr)
EP (1) EP3762727A1 (fr)
JP (1) JP2021516342A (fr)
CA (1) CA3093388A1 (fr)
FR (1) FR3078781B1 (fr)
WO (1) WO2019171010A1 (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946293B1 (en) * 1999-02-10 2005-09-20 Es Cell International Pte Ltd. Progenitor cells, methods and uses related thereto
US6610535B1 (en) * 2000-02-10 2003-08-26 Es Cell International Pte Ltd. Progenitor cells and methods and uses related thereto
US7981625B2 (en) * 2008-04-15 2011-07-19 The Board Of Trustees Of The Leland Stanford Junior University Prostate cancer glycan markers and autoantibody signatures
FR3044680B1 (fr) * 2015-12-02 2017-12-22 Univ Limoges Methode de detection de cellules souches cancereuses
FR3044681B1 (fr) * 2015-12-02 2017-12-22 Univ Limoges Methode d'isolement de cellules souches cancereuses
ES2939850T3 (es) * 2016-07-14 2023-04-27 Uniogen Oy Diagnósticos basados en lectina de cánceres
CN111344570A (zh) * 2017-06-08 2020-06-26 卡西迪亚生物技术公司 分离和检测癌症干细胞的方法

Also Published As

Publication number Publication date
JP2021516342A (ja) 2021-07-01
CA3093388A1 (fr) 2019-09-12
EP3762727A1 (fr) 2021-01-13
US12109248B2 (en) 2024-10-08
WO2019171010A1 (fr) 2019-09-12
FR3078781A1 (fr) 2019-09-13
US20210052697A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
Zhou et al. Wnt signaling pathway in cancer immunotherapy
Liu et al. A dual-site two-photon fluorescent probe for visualizing lysosomes and tracking lysosomal hydrogen sulfide with two different sets of fluorescence signals in the living cells and mouse liver tissues
MA30808B1 (fr) Compositions et procedes permettant de diagnostiquer et de traiter le cancer
WO2018213604A3 (fr) Dosages de diagnostic pour détecter, quantifier et/ou suivre des microbes et d'autres analytes
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
ES2573471T3 (es) 1L1RL-1 como un marcador de enfermedades cardiovasculares
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
CL2011001911A1 (es) Alojamiento para un conjunto de fibra optica, comprende cuerpos superior e inferior, almohadillas de obturacion superior e inferior montadas en una canaleta una de ellas al menos sostenida contra el cuerpo respectivo mediante un medio de retencion y el otro cuerpo posee una superficie de tope con contorno para las almohadillas.
Lindén et al. Terbium-based time-gated Förster resonance energy transfer imaging for evaluating protein–protein interactions on cell membranes
ATE478330T1 (de) Kalibriereinrichtung und farbstoffkit sowie ihre verwendung zur charakterisierung von lumineszenzmesssystemen
FR3078781B1 (fr) Methode d'isolement et de detection de cellules souches cancereuses
Runge et al. Evaluation of single‐cell biomechanics as potential marker for oral squamous cell carcinomas: a pilot study
Shibata et al. Light transmission and spectral distribution through epi-and endozoic algal layers in the brain coral, Favia
AU2003242815A8 (en) Method for the characterisation of circulating tumour cells stemming from solid cancers
WO2022043491A3 (fr) Conjugués comprenant une fraction détectable
Park et al. Development of two-photon fluorescence probe for detecting cyclooxygenase-2 level in human colorectal cancer tissue
WO2018187385A8 (fr) Compositions et procédés de diagnostic du cancer du pancréas
Ren et al. Long-term monitoring of capase-3 activity in living cells based on the FRET probe composed of quantum dot, nanogold and EGF
FR3067466B1 (fr) Methode d'isolement et de detection de cellules souches cancereuses
FR3044681A1 (fr) Methode d'isolement de cellules souches cancereuses
CN107118235A (zh) 近红外发光钌配合物在细胞pH传感中的应用
Abdul et al. Correction: Deep-lumen assay–human lung epithelial spheroid classification from brightfield images using deep learning
WO2019050149A3 (fr) Procédé de dépistage du cancer de la prostate chez un patient au moyen d'un antigène membranaire spécifique de la prostate
WO2023244987A3 (fr) Systèmes et procédés pour effectuer des dosages biologiques à l'aide d'une soupape thermoscellée
KR101962044B1 (ko) 효소 활성 검출용 가변색 이광자 형광 프로브 및 이를 이용한 암질환 진단방법

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20190913

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8